Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vrise Therapeutics Inc. maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, showing a diverse spread of review even with a small number of active matters. This distribution suggests that the company's current filings cover different technical aspects within the biotechnology sector, requiring engagement with multiple specialized units at the office.
The busiest examiner, MCKOY, QUINCY ANDRE, is responsible for 1 busiest examiner pending office action. This indicates that the 2 pending office actions are split equally between the 2 distinct examiners involved in the portfolio's prosecution. For a practitioner, this means managing two separate examiner relationships and navigating the specific requirements of 2 distinct art units simultaneously, rather than centralizing efforts under one reviewer.
In the Biotechnology & Pharmaceuticals field, having the workload split across multiple reviewers can lead to different prosecution timelines and outcomes. Since MCKOY, QUINCY ANDRE is only handling 1 busiest examiner pending office action, no single individual dominates the company's current legal landscape. This balanced workload requires a coordinated strategy to ensure consistency in technical arguments across the 2 distinct art units involved in the current prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 68.4% | +39.8% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18943004 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | MCKOY, QUINCY ANDRE | — |
| 18260928 | SMALL MOLECULES FOR TREATEMENT OF CANCER | LEE, CHIHYI NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18943004 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | MCKOY, QUINCY ANDRE | — |
| 18260928 | SMALL MOLECULES FOR TREATEMENT OF CANCER | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18943004 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | MCKOY, QUINCY ANDRE | 1626 | §102§112 | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18260928 | SMALL MOLECULES FOR TREATEMENT OF CANCER | LEE, CHIHYI NMN | 1628 | §103§112Other | Final Rejection | — | Pending | Jul 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVrise Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Quincy Andre Mckoy has the most, with 1 of Vrise Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
